CurrentCignaPolicy 0577

Esophageal mucosal integrity testing (MiVu) by electrical impedance

Defines Cigna's coverage stance for esophageal mucosal integrity testing using transoral electrical impedance (MiVu system) performed during endoscopy for evaluation of esophageal disorders; applies to health benefit plans administered by Cigna Companies.

Policy Summary

PayerCigna

PolicyEsophageal mucosal integrity testing (MiVu) by electrical impedance

Policy CodePolicy 0577

Change TypeAnnual review — no material changes

Effective DateOct 15, 2024

Next Review DateOct 15, 2025

Key ActionDo not submit claims for esophageal mucosal integrity testing (HCPCS C9777) for coverage as the service is considered experimental/investigational and not covered.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

C9777HCPCS experimental

De Novo 2019FDA De Novo

510(k) 2023510(k)

Annual reviewReview outcome

Coverage Determination

Policy Summary

PayerCigna

PolicyEsophageal mucosal integrity testing (MiVu) by electrical impedance

Policy CodePolicy 0577

Change TypeAnnual review — no material changes

Effective DateOct 15, 2024

Next Review DateOct 15, 2025

Key ActionDo not submit claims for esophageal mucosal integrity testing (HCPCS C9777) for coverage as the service is considered experimental/investigational and not covered.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Esophageal mucosal integrity testing using transoral electrical impedance (HCPCS C9777) is not covered. This service is considered experimental, investigational, or unproven and therefore excluded from coverage under this policy. The exclusion applies to testing performed during esophagoscopy or esophagogastroduodenoscopy using transoral electrical impedance techniques.

Rationale: available evidence and the policy determination do not support this test as a covered diagnostic service; the procedure is categorized as experimental/investigational/unproven and claims billed with HCPCS C9777 will be managed accordingly.

Provider Requirements and Impact

Prior Authorization

Experimental / Investigational Service — Prior Authorization Implications

This service is designated experimental/investigational per the policy; claims for the procedure described by HCPCS code C9777 are not supported by sufficient evidence and are not considered a covered benefit under this policy. Providers should expect that requests for coverage of this service will not meet medical necessity criteria.

Affected code: HCPCS C9777

Denial Risk

Denial Risk for Experimental Service

Claims for HCPCS code C9777 will be denied as not covered under this policy because the service is considered experimental/investigational.

Do not expect reimbursement for HCPCS C9777 under Cigna-administered plans when this policy applies.

Billing Rule

Billing and Coding Note

When submitting claims, use the most appropriate and current codes effective on the date of service. Reimbursement is allowed only when services are billed with covered diagnosis and/or procedure codes consistent with the applicable Coverage Policy and the member's benefit plan. Services billed with codes that are not covered by this policy (including C9777) will be denied as not covered.

Verify the member's specific benefit plan terms and any applicable exclusions before billing.
If appealing a denial, include clinical rationale and supporting evidence that addresses the experimental/investigational determination.

Documentation Required

Provider Action Note

Providers should review the member's benefit plan document for any plan-specific exclusions and be aware that some Cigna business lines only provide utilization review and do not make coverage determinations. Medical directors retain discretion for individual coverage decisions; however, services designated experimental/investigational per this policy are not covered.

Confirm whether the specific Cigna entity administers coverage determinations or only provides utilization review.
Include complete clinical documentation with any prior authorization or appeal request.

Background and Evidence

Mucosal impedance (MI) testing measures esophageal mucosal integrity by recording electrical impedance of the esophageal epithelium. Changes in mucosal integrity—such as increased permeability from dilated intercellular spaces—have been proposed as physiologic markers in conditions like gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE).

The MiVu approach captures real-time impedance measurements during endoscopy via a transoral device placed during esophagoscopy or esophagogastroduodenoscopy. It is described as an adjunctive tool for evaluating esophageal disorders rather than a standalone diagnostic screening test. Despite FDA device clearances referenced in the broader literature, the policy classifies testing performed with transoral electrical impedance (HCPCS C9777) as experimental and not a covered benefit.

Definitions

Mucosal Integrity (MI) — definition and clinical correlations

DefinitionMucosal Integrity (MI): electrical impedance measurements that reflect esophageal mucosal permeability and are inversely correlated with dilated intercellular spaces (DIS).

Pathophysiology correlationMI is affected by dilated intercellular spaces (spongiosis); increasing DIS produces lower impedance values (inverse correlation).

Clinical associationsProposed method to aid diagnosis of gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE).

Role in evaluationUsed as an adjunct during endoscopy to assess epithelial integrity and support evaluation of esophageal disorders; not a standalone diagnostic test per vendor/FDA descriptions referenced elsewhere.

MiVu System — device description and intended use

Device componentsMiVu Mucosal Integrity Testing System: a clinical system comprising a balloon probe (or Endo Cap accessory) with radial and axial sensors and proprietary software to display real-time impedance values, a mucosal integrity contour, and disease probability.

Probe designMiVu Balloon Probe incorporates radial and axial sensors mounted at 180-degree intervals along a 10 cm segment of the esophagus to measure mucosal integrity.

Intended useIntended for use during endoscopy by trained gastroenterologists, surgeons, and endoscopy personnel to obtain real-time measurements of esophageal epithelial integrity as an adjunct for evaluation of esophageal disorders.

Regulatory notesFDA: MI Test System received De Novo Class II approval (Dec 23, 2019); MiVu Esophageal Endo Cap received 510(k) clearance (Apr 25, 2023).

OpenPayer

Esophageal mucosal integrity testing (MiVu) by electrical impedance

Coverage Determination

Billing and Coding

Provider Requirements and Impact

Background and Evidence

Definitions

Policy Revision History